Biora Therapeutics, Inc. (BIOR)
NASDAQ: BIOR · Real-Time Price · USD
2.950
-0.380 (-11.41%)
At close: Nov 4, 2024, 4:00 PM
2.990
+0.040 (1.35%)
After-hours: Nov 4, 2024, 7:38 PM EST
Company Description
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States.
The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.
The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline.
Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Biora Therapeutics, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jun 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Aditya Mohanty |
Contact Details
Address: 4330 La Jolla Village Drive, Suite 300 San Diego, California 92122 United States | |
| Phone | 833 727 2841 |
| Website | bioratherapeutics.com |
Stock Details
| Ticker Symbol | BIOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001580063 |
| CUSIP Number | 74319F107 |
| ISIN Number | US74319F3055 |
| Employer ID | 27-3950390 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Aditya P. Mohanty M.B.A. | Chief Executive Officer and Director |
| Eric d'Esparbes | Chief Financial Officer |
| Clarke Neumann J.D. | Senior Vice President, General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 424B5 | Filing |
| Oct 29, 2024 | 424B3 | Prospectus |
| Oct 29, 2024 | 424B3 | Prospectus |
| Oct 29, 2024 | 424B3 | Prospectus |
| Oct 29, 2024 | 424B3 | Prospectus |
| Oct 29, 2024 | 424B3 | Prospectus |
| Oct 23, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 11, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 11, 2024 | 8-K | Current Report |